Evernorth announces another step forward in lowering drug prices by making a Stelara biosimilar available at $0 out of pocket for patients early next year
CICigna(CI) Prnewswire·2024-09-05 18:00

Estimated to save individual Accredo patients around 4,000peryearBiosimilarpricewillbemorethan804,000 per year Biosimilar price will be more than 80% lower than Stelara list priceAccredo patients benefit from the specialty pharmacy's best-in-class clinical supportBLOOMFIELD, Conn., Sept. 5, 2024 /PRNewswire/ -- Evernorth Health Services announced that it plans to have a Stelara biosimilar available for 0 out of pocket for eligible patients of its specialty pharmacy, Accredo, beginning in early 2025. The interchangeable biosimilar will be produced ...